JCM Free Medline Searching
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rouet, F.
Right arrow Articles by Gessain, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rouet, F.
Right arrow Articles by Gessain, A.

Journal of Clinical Microbiology, April 2001, p. 1247-1253, Vol. 39, No. 4
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.4.1247-1253.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Serological, Epidemiological, and Molecular Differences between Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Seropositive Healthy Carriers and Persons with HTLV-I Gag Indeterminate Western Blot Patterns from the Caribbean

François Rouet,1,dagger Laurent Meertens,2 Géry Courouble,3 Cécile Herrmann-Storck,4 Raymond Pabingui,4 Bruno Chancerel,1 Adda Abid,1 Michel Strobel,4 Philippe Mauclere,2 and Antoine Gessain2,*

Etablissement Français du Sang,1 Laboratoire de Biologie,3 and Service Maladies Infectieuses et Dermatologie,4 C. H. U. de Pointe-à-Pitre, Guadeloupe, and Unité d'Oncologie Virale, Institut Pasteur, Paris,2 France

Received 3 November 2000/Returned for modification 17 December 2000/Accepted 16 January 2001

To investigate the significance of serological human T-cell lymphotropic virus type 1 (HLTV-1) Gag indeterminate Western blot (WB) patterns in the Caribbean, a 6-year (1993 to 1998) cross-sectional study was conducted with 37,724 blood donors from Guadeloupe (French West Indies), whose sera were routinely screened by enzyme immunoassay (EIA) for the presence of HTLV-1 and -2 antibodies. By using stringent WB criteria, 77 donors (0.20%) were confirmed HTLV-1 seropositive, whereas 150 (0.40%; P < 0.001) were considered HTLV seroindeterminate. Among them, 41.3% (62) exhibited a typical HTLV-1 Gag indeterminate profile (HGIP). Furthermore 76 (50.7%) out of the 150 HTLV-seroindeterminate subjects were sequentially retested, with a mean duration of follow-up of 18.3 months (range, 1 to 70 months). Of these, 55 (72.4%) were still EIA positive and maintained the same WB profile whereas the others became EIA negative. This follow-up survey included 33 persons with an HGIP. Twenty-three of them (69.7%) had profiles that did not evolve over time. Moreover, no case of HTLV-1 seroconversion could be documented over time by studying such sequential samples. HTLV-1 seroprevalence was characterized by an age-dependent curve, a uniform excess in females, a significant relation with hepatitis B core (HBc) antibodies, and a microcluster distribution along the Atlantic coast of Guadeloupe. In contrast, the persons with an HGIP were significantly younger, had a 1:1 sex ratio, did not present any association with HBc antibodies, and were not clustered along the Atlantic façade. These divergent epidemiological features, together with discordant serological screening test results for subjects with HGIP and with the lack of HTLV-1 proviral sequences detected by PCR in their peripheral blood mononuclear cell DNA, strongly suggest that an HGIP does not reflect true HTLV-1 infection. In regard to these data, healthy blood donors with HGIP should be reassured that they are unlikely to be infected with HTLV-1 or HTLV-2.


* Corresponding author. Mailing address: Unité d'Oncologie Virale, Département des Rétrovirus, 28, rue du Dr Roux, 75724 Paris Cedex 15, France. Phone: (33) 01 45 68 89 37. Fax: (33) 01 40 61 34 65. E-mail: agessain{at}pasteur.fr.

dagger Present address: CeDReS, C. H. U. de Treichville, Abidjan, Ivory Coast.


Journal of Clinical Microbiology, April 2001, p. 1247-1253, Vol. 39, No. 4
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.4.1247-1253.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.